RSS-Feed abonnieren
DOI: 10.1055/s-2003-36667
Chirurgie - Fisteln
Surgery FistulasPublikationsverlauf
Publikationsdatum:
16. Januar 2003 (online)
![](https://www.thieme-connect.de/media/zfg/200301/lookinside/thumbnails/10.1055-s-2003-36667-1.jpg)
Präoperative Diagnostik vor abdominellen Operationen
Konsens
Ein komplettes Staging ist obligat zur Sicherung der Diagnose. Wenn die Diagnose gesichert ist, sollten präoperativ eine Sonographie und Koloskopie (maximal vor einem halben Jahr), bei Abszess-Verdacht CT bzw. MRT (möglichst in Interventionsbereitschaft) vorliegen. Bei geplantem laparoskopischen Vorgehen ist ein Sellink oder ein MR-Sellink obligat (max. ein halbes Jahr alt) (C).
Erläuterung
Vor abdominellen resezierenden, explorierenden und ggf. mit Strikturoplastiken verbundenen Eingriffen sind die folgenden diagnostischen Untersuchungen abdingbar. Sollte die Diagnose noch nicht komplett gesichert sein, so muss ein komplettes Staging erfolgen. Dieses Staging beinhaltet: Koloskopie, Röntgen-Sellink des Dünndarms oder MR-Sellink und Ösophago-Gastro-Duodenoskopie [1] [6]. Wenn eine Diagnose uneingeschränkt gesichert ist, muss kein komplettes Staging erfolgen. Vielmehr sind hier die folgenden Verfahren mit der entsprechenden Fragestellung erforderlich: Abdomen-Sonographie zum groben Ausschluss eines Abszesses, bei Abszessverdacht eine Computertomographie bzw. eine MRT des Abdomens. Hierbei sollte von radiologischer Seite immer Interventionsbereitschaft bestehen, um ggf. drainierbare intraabdominelle Abszesse interventionell mit einer ausreichend großen Drainage zu versorgen.
Die Koloskopie sollte nicht älter ein halbes Jahr alt sein, da sich das Kolon intraoperativ nur eingeschränkt beurteilen lässt. Insbesondere Rektum und Sigma sind von außen schlecht zu beurteilen. Ein hier ggf. zusätzlich vorhandener Befund würde unter Umständen das Resektionsausmaß erweitern [7]. Ferner ist hinsichtlich eines geplanten laparoskopischen Vorgehens ein maximal 6 Monate alter Sellink des Dünndarms oder ein MRT-Sellink obligat. Diese zusätzliche Diagnostik ist deswegen erforderlich, da sich laparoskopisch der Dünndarm schlechter explorieren und palpieren lässt [8].
Literatur
- 1 Hammer B. Current developments in the diagnosis and therapy of Crohn disease and ulcerative colitis. Schweiz Med Wochenschr. 1994; 124 452-460
- 2 Bauer J J, Harris M T, Grumbach N M. et al . Laparoscopic-assisted intestinal resection for Crohn’s disease. Which patients are good candidates?. J Clin Gastroenterol. 1996; 23 44-46
- 3 Gualdi G F, Volpe A, Polettini E. et al . Computerized tomography and magnetic resonance in the evaluation of patients with Crohn disease. Their role in the identification, assessment of extent and management of the disease. Clin Ter. 1994; 144 545-551
- 4 Pompili G G. et al . Computerized tomography in the diagnosis of Crohn disease. Radiol Med (Torino). 1994; 88 44-48
- 5 Raskin J B. Recent developments in gastrointestinal endoscopy. Postgrad Med. 1975; 57 85-92
- 6 Schunk K. et al . Follow-up of Crohn’s disease: can hydro-MRI replace fractionated gastrointestinal passage examination?. Röfo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 1997; 166 389-396
- 7 McLeod R S. et al . Risk and significance of endoscopic/radiological evidence of recurrent Crohn’s disease. Gastroenterology. 1997; 113 1823-1827
- 8 Serizawa H. et al . Laparoscopically assisted ileocecal resection for Crohn’s disease associated with intestinal stenosis and ileovesical fistula. J Gastroenterol. 1996; 31 425-430
- 9 Goligher J C, de Dombal F T, Burton I. Crohn’s disease, with special reference to surgical management. Prog Surg. 1972; 10 1-23
- 10 Goligher J C. Inflammatory disease of the bowel: results of resection for Crohn’s disease. Dis Colon Rectum. 1976; 19 584-587
- 11 Herfarth C, Ewe K. Surgical treatment of Crohn’s disease. Chirurg. 1977; 48 569-576
- 12 Yamamoto T, Allan R N, Keighley M R. Risk factors for intra-abdominal sepsis after surgery in Crohn’s disease. Dis Colon Rectum. 2000; 43 1141-1145
- 13 Bernstein C N, Blanchard J F, Kliewer E. et al . Cancer risk in patients with inflammatory bowel disease. Cancer. 2001; 91 854-862
- 14 Greenstein A J. et al . Colorectal cancer in regional ileitis. Q J Med. 1987; 62 33-40
- 15 Muller-Decker K. et al . Cellular localization of cyclo-oxygenase isozymes in Crohn’s disease and colorectal cancer. Int J Colorectal Dis. 1999; 14 212-218
- 16 Nikias G. et al . Crohn’s disease and colorectal carcinoma: rectal cancer complicating longstanding active perianal disease. Am J Gastroenterol. 1995; 90 216-219
- 17 Ribeiro M B. et al . Colorectal adenocarcinoma in Crohn’s disease. Ann Surg. 1996; 223 186-193
- 18 Sheil F O, Clark C G, Goligher J C. Adenocarcinoma associated with Crohn’s disease. Br J Surg. 1968; 55 53-58
- 19 Hirschfeld S, Clearfield H R. Pharmacologic therapy for inflammatory bowel disease. Am Fam Physician. 1995; 51 1971-1975
- 20 Kornbluth A, George J, Sachar D B. Immunosuppressive drugs in Crohn’s disease. Gastroenterologist. 1994; 2 239-246
- 21 Lamers C B, Griffioen G, van Hogezand R A. et al . Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1999; 230 111-115
- 22 Rieger N, Stahl J, Wattchow D. Intractable Crohn’s colitis and perianal disease responding to cyclophosphamide and epirubicin. Dig Dis Sci. 1997; 42 2367-2369
- 23 Stange E F. The traditional immunosuppressors. Campieri et al Inflammatory bowel disease. A clinical case approach to pathophysiology, diagnosis and treatment Dordrecht; Kluwer Academic Publishers 2002: 201-205
- 24 Farkas S, Bero T, Kersak J. et al . Life-threatening gastrointestinal bleeding in Crohn disease. Orv Hetil. 1998; 139 2261-2262
- 25 Isbister W H. Colorectal operative experience in general surgical training. Int J Colorectal Dis. 1999; 14 69-72
- 26 Wolff B G. Crohn’s disease: the role of surgical treatment. Mayo Clin Proc. 1986; 61 292-295
- 27 Yamamoto T, Keighley M R. Long-term outcome of total colectomy and ileostomy for Crohn disease. Scand J Gastroenterol. 1999; 34 280-286
- 28 Buhr H J, Kallinowski F, Post S. et al .Recurrent Crohn - impact of surgical strategy. Lochs H, Schölmerich G IBD: Pathophysiology as basis of treatment Amsterdam; Academic Press 1993: 122-129
- 29 Buhr H J, Kroesen A J, Herfarth C. Surgical therapy of recurrent Crohn disease. Chirurg. 1995; 66 764-773
- 30 Sonnenberg A, Gavin M W. Timing of surgery for enterovesical fistula in Crohn’s disease: decision analysis using a time-dependent compartment model. Inflamm Bowel Dis. 2000; 6 280-285
- 31 Yamamoto T, Keighley M R. Enterovesical fistulas complicating Crohn’s disease: clinicopathological features and management. Int J Colorectal Dis. 2000; 15 211-215
- 32 Lee P Y. et al . Vaginal fistula following restorative proctocolectomy. Dis Colon Rectum. 1997; 40 752-759
- 33 Makowiec F, Jehle E C, Becker H D. et al . Clinical course after transanal advancement flap repair of perianal fistula in patients with Crohn’s disease. Br J Surg. 1995; 82 603-606
- 34 Ozuner G, Hull T L, Cartmill J. et al . Long-term analysis of the use of transanal rectal advancement flaps for complicated anorectal/vaginal fistulas. Dis Colon Rectum. 1996; 39 10-14
- 35 Scott N A, Nair A, Hughes L E. Anovaginal and rectovaginal fistula in patients with Crohn’s disease. Br J Surg. 1992; 79 1379-1380
- 36 Ozuner G, Fazio V W, Lavery I C. et al . Reoperative rates for Crohn’s disease following strictureplasty. Long-term analysis. Dis Colon Rectum. 1996; 39 1199-1203
- 37 Ewe K, Herfarth C, Malchow H. et al . Postoperative recurrence of Crohn’s disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion. 1989; 42 224-232
- 38 Fazio V W. et al . Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg. 1996; 224 563-571
- 39 Borley N R, Mortensen N J, Jewell D P. Preventing postoperative recurrence of Crohn’s disease. Br J Surg. 1997; 84 1493-1502
- 40 Hashemi M, Novell J R, Lewis A A. Side-to-side stapled anastomosis may delay recurrence in Crohn’s disease. Dis Colon Rectum. 1998; 41 1293-1296
- 41 Scott N A, Sue-Ling H M, Hughes L E. Anastomotic configuration does not affect recurrence of Crohn’s disease after ileocolonic resection. Int J Colorectal Dis. 1995; 10 67-69
- 42 Yamamoto T, Bain I M, Mylonakis E. et al . Stapled functional end-to-end anastomosis versus sutured end-to-end anastomosis after ileocolonic resection in Crohn disease. Scand J Gastroenterol. 1999; 34 708-713
- 43 Hildebrandt U, Ecker K W, Feifel G. Minimally invasive surgery and Crohn disease. Chirurg. 1998; 69 915-921
- 44 Schmidt C M. et al . Laparoscopic surgery for Crohn’s disease: reasons for conversion. Ann Surg. 2001; 233 733-739
- 45 Young-Fadok T M, HallLong K, McConnell E J. et al . Advantages of laparoscopic resection for ileocolic Crohn’s disease. Improved outcomes and reduced costs. Surg Endosc. 2001; 15 450-454
- 46 Prabhakar L P, Laramee C, Nelson H. et al . Avoiding a stoma: role for segmental or abdominal colectomy in Crohn’s colitis. Dis Colon Rectum. 1997; 40 71-78
- 47 Chevalier J M. et al . Colectomy and ileorectal anastomosis in patients with Crohn’s disease. Br J Surg. 1994; 81 1379-1381
- 48 Longo W E, Oakley J R, Lavery I C. et al . Outcome of ileorectal anastomosis for Crohn’s colitis. Dis Colon Rectum. 1992; 35 1066-1071
- 49 Panis Y. et al . Ileal pouch/anal anastomosis for Crohn’s disease. Lancet. 1996; 347 854-857
- 50 Kroesen A J, Buhr H J. Anorectal fistulas in Crohn disease. Zentralbl Chir. 1999; 124 (Suppl 2) 34-38
- 51 Beets-Tan R G. et al . Preoperative MR imaging of anal fistulas: Does it really help the surgeon?. Radiology. 2001; 218 75-84
- 52 Fazio V W, Tjandra J J. The management of perianal diseases. Adv Surg. 1996; 29 59-78
- 53 O’Donoghue D P, Hyland J M. Perianal Crohn’s disease (comment). Eur J Gastroenterol Hepatol. 1997; 9 235-236
- 54 Sangwan Y P, Schotz D J Jr, Murray J J. et al . Perianal Crohn’s disease. Results of local surgical treatment. Dis Colon Rectum. 1996; 39 529-535
- 55 Lichtenstein G R. Treatment of fistulizing Crohn’s disease. Gastroenterology. 2000; 119 1132-1147
- 56 Bernstein L H, Frank M S, Brandt L J. et al . Healing of perineal Crohn’s disease with metronidazole. Gastroenterology. 1980; 79 357-365
- 57 Brandt L, Bernstein L, Boley S. et al . Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology. 1982; 83 383-387
- 58 Schneider M U, Laudage G, Guggenmoos-Holzman I. et al . Metronidazol in der Behandlung des Morbus Crohn. Dtsch Med Wochenschr. 1985; 110 1724-1730
- 59 Stahlberg D, Barany, Einarsson K. et al . Neurophysiologic studies of patients with Crohn’s disease on long-term treatment with metronidazole. Scand J Gastroenterol. 1991; 26 219-224
- 60 Turunen U, Farkkila M, Seppala K. Long-term treatment of perianal or fistulous Crohn’s disease with Ciprofloxacin (suppl 148). Scand J Gastroenterol. 1989; 24 144
- 61 Solomon M, McLeod R, O’Connor B. et al . Combination ciprofloxacin and metronidazole in severe perianal Crohn’s disease. Can J Gastroenterol. 1993; 571-573
- 62 Present D H, Korelitz B I, Wisch N. et al . Treatment of Crohn’s disease with 6-mercaptopurine: a long-term randomized double blind study. N Engl J Med. 1980; 302 981-987
- 63 Korelitz B I, Present D H. Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci. 1985; 30 58-64
- 64 O’Brien J J, Bayless T M, Bayless J A. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn’s disease. Gastroenterology. 1991; 101 39-46
- 65 Egan U, Sandborn W J, Tremaine W J. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterol. 1998; 93 442-448
- 66 Hanauer S B, Smith M B. Rapid closure of Crohn’s disease fistulas with continous intravenous cyclosporin A. Am J Gastroenterol. 1993; 88 646-649
- 67 Present D H, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci. 1994; 29 374-380
- 68 Lowry P W, Weaver A L, Tremaine W J. et al . Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis. 1995; 5 239-245
- 69 Sandborn W J. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol. 1997; 92 876-879
- 70 Fellermann K, Ludwig D, Stahl M. et al . Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (TK506). Am J Gastroenterol. 1998; 93 1860-1866
- 71 Muhadevan U, Marion J, Present D H. The place of methotrexate in the treatment of refractory Crohn’s disease (abstr). Gastroenterology. 1997; 112 A1031
- 72 Present D H, Rutgeerts P, Targan S. et al . Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999; 340 1398-1405
- 73 Fickert P, Hinterleitner T A, Wenzl H H. et al . Mycophenolate mofetil in patients with Crohn’s disease. Am J Gastroenterol. 1998; 93 2529-2532
- 74 Ehrenpreis E D, Kane S V, Cohen L B. et al . Thalidomine therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology. 1999; 117 1271-1277
- 75 Vasiliauskas E A, Kam L Y, Abreu-Martin M T. et al . an open-label pilot study of low-dose thalidomide in chronically acitve, steroid-dependent Crohn’s disease. Gastroenterology. 1999; 117 1278-1287
- 76 Lavy A, Weisz G, Adir Y. et al . Hyperbaric oxygen for perianal Crohn’s disease. J Clin Gastroenterol. 1994; 19 202-205
- 77 Colombel J F, Mathieu D, Bouault J M. et al . Hyperbaric oxygenation in severe perineal Crohn’s disease. Dis Colon Rectum. 1955; 38 609-614
- 78 Halverson A L. et al . Repair of recurrent rectovaginal fistulas. Surgery. 2001; 130 753-757